An interventional study of Botox injection and Mandibular stabilization splint in Mandibular Splint, Botox and Lateral Pterygoid, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-08-16.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing botulinum toxin type A in Temporomandibular Joint Disorders — 3 open to participants now, 3 under way, none of them phase 3. botulinum toxin type A · Temporomandibular Joint Disorders.
Among the 11 studies testing botulinum toxin type A in Temporomandibular Joint Disorders, this one is the 7th largest by planned enrollment, is one of 3 that started in 2024, is one of 5 with no phase, and was the 6th registered.
593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.
Browse Temporomandibular Joint Disorders studies →3 of the 11 studies testing botulinum toxin type A in Temporomandibular Joint Disorders are open now, in 3 countries. Recruiting first, the newest first:
Riphah International University · Sites in Pakistan
Ages 18–60
Karolinska Institutet · Sites in Sweden
Ages 20–45
By country, each count listing its studies:
botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 76 Temporomandibular Joint Disorders studies recruiting now, 26 (34%) set no upper age limit and 46 (61%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 2 · Phase 4 1
First in 2015; this study’s year is marked. 3 started in 2024.
This study's planned enrollment of 33 is below the median of 45 across 417 interventional studies indexed under Temporomandibular Joint Disorders.
Median enrollment 72 across the 11 interventional studies. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 10 most frequent:
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
30 studies in Temporomandibular Joint Disorders by Cairo University: 8 open now, 9 under way, none of them phase 3. Of 11 finished, 0 (0%) have results posted.
Among the 30 studies in Temporomandibular Joint Disorders by Cairo University, this one is the 6th largest by planned enrollment of the 21 interventional ones that give a count, is one of 6 that started in 2024, is one of 20 with no phase, and was the 20th registered.
Cairo University’s Temporomandibular Joint Disorders studies by the year they started, since 2015.
2 of the studies testing botulinum toxin type A in Temporomandibular Joint Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07847541Riphah International UniversityClinical Evaluation of Botulinum Toxin a in the Management of Temporomandibular Myofascial Pain | 2026-12-15 |
| NCT05720065Karolinska InstitutetPeripheral TMD Pain Mechanisms and the Effect by Botulinum Toxin A | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies testing botulinum toxin type A in Temporomandibular Joint Disorders, from their registry updates:
Among Cairo University’s 30 in Temporomandibular Joint Disorders:
This tab as a report to print or save as PDF → With an account.
The study aims to compere mandibular splint versus botox injection in lateral pterygoid on cervical muscle activity in patients with temporomandibular disorders
Temporomandibular disorders (TMD) are common chronic musculoskeletal pain conditions among orofacial pain, consisting of a group of conditions associated with pain and dysfunction of the temporomandibular joint (TMJ) and masticatory muscles. Temporomandibular joint displacement, also known as internal disc derangement, is an abnormal relationship between the articular disc, the mandibular condyle, and the mandibular fossa. The most frequent displacement of the disc is anterior to the mandibular condyle however, in rare cases it can be posteriorly.
Occlusal splint treatment is generally considered to be a basic treatment for Temporomandibular disorders. It could promote correction of the vertical dimension, maxillo-mandibular realignment, temporomandibular joint repositioning and cognitive awareness. Although various splints are currently available, the most used are stabilization splints and anterior repositioning splints.
Injection of BTX-A in LP muscle, considering the different methods, frequencies and injection dosages used in different studies, would decrease the clicks and other TMJ-related disorders such as pain, hyperactivity, and dysfunction. Based on the present review, most studies about the injection of botulinum toxin in LP muscle reported cases or were done as quasi-experimental studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be treated by Botox injection in lateral pterygoid muscle and medications like muscle relaxants, antidepressants, and nonsteroidal anti-inflammatory drugs. A Botox-A vial was diluted with normal saline to a concentration of 10 U per 0.1 mL for injection in a 1-ml insulin syringe. This will be injected into the ipsilateral lateral pterygoid muscle
Drug: Botox injection
Patients will be treated by mandibular stabilization splint and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
Drug: Mandibular stabilization splint
Patients will be treated by medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
Drug: Muscle relaxant
Patients will be treated by Botox injection in lateral pterygoid muscle and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs. A Botox-A vial was diluted with normal saline to a concentration of 10 U per 0.1 mL for injection in a 1-ml insulin syringe. This will be injected into the ipsilateral lateral pterygoid muscle.
Patients will be treated by mandibular stabilization splint and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
Patients will be treated by medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
Muscle activity of upper trapizieus and sternocleidomastoid
Muscle activity of upper trapizieus and sternocleidomastoid will be recorded before and after injection for 3 months by neurosoft Electromyography
Time frame: After injection for 3 months.
Amplitude of muscle activity
Amplitude of muscle activity will be recorded before and after injection for 3 months by neurosoft Electromyography.
Time frame: After injection for 3 months.
Root mean square of muscle activity
Root mean square of muscle activity will be recorded before and after injection for 3 months by neurosoft Electromyography.
Time frame: After injection for 3 months.
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
Time frame: After the end of study for one year.
Access criteria: The data will be available upon a reasonable request from the corresponding author.
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Feb 2025, 5 months after the start.
Of 244 non-industry interventional studies with no phase under Temporomandibular Joint Disorders, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's planned 5 months is below that.
Counting every sponsor, half of 248 studies reached it within 11 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A
Temporomandibular Joint Disorders →